Современные рекомендации по использованию заместительной гормональной терапии у женщин в менопаузе

Исполнительный комитет Международной ассоциации по менопаузе разработал положение, пред? ставленное на 4-й рабочей встрече Международной ассоциации по менопаузе в декабре 2003 г. В данном положении был представлен современный обзор всей доступной информации из наблюдательных, рандомизированных и доклинических исследований. В феврале 2004 г. Исполнительным комитетом Международной ассоциации по менопаузе было утверждено информационное послание, адресованное врачам-специалистам и научным работникам, занимающимся проблемами лечения и профилактики проявлений менопаузального синдрома у женщин старшей возрастной группы и использующих в повседневной практике ЗГТ.

заместительная гормональная терапия, менопауза, рекомендации

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288:321-33

2. Manson JE, Hsia J, Johnson КС, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-34

3. Chlebowski RT, Hendrix SL, Longer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. J Am Med Assoc 2003; 289:3243-53

4. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362:419-27

5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary disease in postmenopausal women. J Am Med Assoc 1 998; 280:605-1 3

6. Herrington DM, Reboussin DR, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000; 343:522-9

7. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1 839-54

8. Naftolin F, Taylor HS, Karas R. Early initiation of hormone therapy and clinical cardioprotection: the Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004: in press

9. Shapiro S. Effects of hormone replacement therapy on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence. In Schneider HPG, Naftolin F, eds. Climacteric Medicine Where Do We Go? Proceedings of the 4th Workshop of the International Menopause Society. London: Parthenon Publishing, 2004: in press

10. Karas RH, Clarkson ТВ. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 2003; 10:8-12

11. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133:933-41

12. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone treatment and mortality. N Engl J Med 1997; 336:1769-75

13. Joakimsen O, B_naa KH, Stensland-Bugge E, Jacobsen BK. Populationbased study of age at menopause and ultrasound assessed carotid atherosclerosis. J Clin Epidemiol 2000; 53:525-30

14. Ни FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000; 343:530-7

15. Mack WJ, Hameed AB, Xiang M, et al. Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. Atherosclerosis 2003; 168:91-8

16. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary atherosclerosis by 1 7 estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990; 10; 1051 -7